Multicenter retrospective study on the use of Curebest™ 95GC Breast for estrogen receptor-positive and node-negative early breast cancer

BMC Cancer

卷:21

Koji Arihiro¹  Seiki Takashima²  Shozo Ohsumi²  Mina Takahashi²  Fumine Tsukamoto³  Masayuki Yoshida⁴  Ken-ichi Ito⁵  Takaaki Oba⁵  Takayuki Kinoshita⁶  Keisuke Yamagishi⁷  Kazuki Kishi⁷ 

[1] Department of Anatomical Pathology, Hiroshima University Hospital;

[2] Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center;

[3] Department of Breast and Endocrine Surgery, Japan Community Health care Organization Osaka Hospital;

[4] Department of Pathology and Clinical Laboratories, National Cancer Center Hospital;

[5] Department of Surgery, Division of Breast and Endocrine Surgery, Shinshu University School of Medicine;

[6] Division of Breast Surgery, National Hospital Organization Tokyo Medical Center;

[7] Sysmex Corporation;

关键词: ER-positive breast cancer;    Curebest™ 95GC breast;    DNA microarrays;    Breast cancer staging;    Node-negative breast cancer;    Prognostic prediction;   

DOI  :  10.1186/s12885-021-08778-5

来源: DOAJ

【 摘 要 】

Abstract Background The benefits of postoperative chemotherapy in patients with estrogen receptor (ER)-positive breast cancer remain unclear. The use of tumor grade, Ki-67, or ER expression failed to provide an accurate prognosis of the risk of relapse after surgery in patients. This study aimed to evaluate whether a multigene assay Curebest™ 95GC Breast (95GC) can identify the risk of recurrence and provide more insights into the requirements for chemotherapy in patients. Methods This single-arm retrospective multicenter joint study included patients with ER-positive, node-negative breast cancer who were treated at five facilities in Japan and had received endocrine therapy alone as adjuvant therapy. The primary lesion specimens obtained during surgery were analyzed using the 95GC breast cancer multigene assay. Based on the 95GC results, patients were classified into low-risk (95GC-L) and high-risk (95GC-H) groups. Results The 10-year relapse-free survival rates were 88.4 and 59.6% for the 95GC-L and 95GC-H groups, respectively. Histologic grade, Ki-67, and PAM50 exhibited a significant relationship with the 95GC results. The segregation into 95GC-L and 95GC-H groups within established clinical factors can identify subgroups of patients using histologic grade or PAM50 classification with good prognosis without receiving chemotherapy. Conclusions Based on the results of our retrospective study, 95GC could be used to evaluate the long-term prognosis of ER-positive, node-negative breast cancer. Even though further prospective validation is necessary, the inclusion of 95GC in clinical practice could help to select optimal treatments for breast cancer patients and identify those who do not benefit from the addition of chemotherapy, thus avoiding unnecessary treatment.

【 授权许可】

Unknown